Since Candace Johnson’s appointment as president and CEO of the Roswell Park Cancer Institute in February 2015, the institute has recruited 22 new faculty members and promoted 19 faculty members into senior leadership positions.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
